{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:40:18Z","timestamp":1787002818150,"version":"build-2736575974"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Elevated expression of transglutaminase 2 (TGase 2, EC 2.3.2.13, protein-glutamine \u03b3-glutamyltransferase, gene name\n                    <jats:italic>TGM2<\/jats:italic>\n                    ) is known as one of the most upregulated genes during epithelial-mesenchymal transition (EMT) in ovarian cancer. Despite initial complete responses to conventional chemotherapy, ovarian cancer often recurs with metastasis, presenting a significant clinical challenge. Drug-resistant ovarian cancer cells exhibit markedly higher levels of TGase 2 compared to normal ovarian epithelium, which is associated with EMT activation, enabling them to evade chemotherapy effects. Intracellular TGase 2 is recognized as a key factor in maintaining the mesenchymal phenotype. Therefore, while EMT expression can be effectively reversed by inhibiting TGase 2, the underlying mechanism of this effect remains unclear. We found that TGase 2 promotes EMT by directly binding to glycogen synthase kinase-3\u03b2 (GSK3\u03b2), promoting the stabilization of \u03b2-catenin. Domain mapping revealed that the N-terminus of TGase 2 interacts with the mid-region of GSK3\u03b2, leading to the autophagic degradation of GSK3\u03b2. Pharmacological disruption of this N-terminal interaction by streptonigrin, in combination with standard chemotherapy, extended overall survival in a xenograft model of ovarian cancer. This study identified TGase 2 as a pivotal regulator of EMT-driven metastasis and drug resistance.\n                  <\/jats:p>","DOI":"10.1038\/s41419-026-08447-0","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T14:40:36Z","timestamp":1770043236000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Transglutaminase 2 exacerbates ovarian cancer survival by directly inactivating GSK3\u03b2"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5573-742X","authenticated-orcid":false,"given":"Ho","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joon Hee","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun Jung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyun","family":"Heo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi Kyung","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong Hwan","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1270-8439","authenticated-orcid":false,"given":"Byung Il","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong In","family":"Yook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4021-2206","authenticated-orcid":false,"given":"Soo-Youl","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,2]]},"reference":[{"key":"8447_CR1","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1002\/ijc.34002","volume":"151","author":"CJ Cabasag","year":"2022","unstructured":"Cabasag CJ, Fagan PJ, Ferlay J, Vignat J, Laversanne M, Liu L, et al. Ovarian cancer today and tomorrow: a global assessment by world region and Human Development Index using GLOBOCAN 2020. Int J Cancer. 2022;151:1535\u201341.","journal-title":"Int J Cancer"},{"key":"8447_CR2","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.3390\/ijms25031845","volume":"25","author":"V Tavares","year":"2024","unstructured":"Tavares V, Marques IS, Melo IG, Assis J, Pereira D, Medeiros R. Paradigm shift: a comprehensive review of ovarian cancer management in an era of advancements. Int J Mol Sci. 2024;25:1845.","journal-title":"Int J Mol Sci"},{"key":"8447_CR3","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.semcancer.2020.08.013","volume":"77","author":"M McMullen","year":"2021","unstructured":"McMullen M, Madariaga A, Lheureux S. New approaches for targeting platinum-resistant ovarian cancer. Semin Cancer Biol. 2021;77:167\u201381.","journal-title":"Semin Cancer Biol"},{"key":"8447_CR4","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s00280-017-3501-8","volume":"81","author":"AJ Cortez","year":"2018","unstructured":"Cortez AJ, Tudrej P, Kujawa KA, Lisowska KM. Advances in ovarian cancer therapy. Cancer Chemother Pharmacol. 2018;81:17\u201338.","journal-title":"Cancer Chemother Pharmacol"},{"key":"8447_CR5","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3389\/fonc.2012.00033","volume":"2","author":"B Davidson","year":"2012","unstructured":"Davidson B, Trope CG, Reich R. Epithelial-mesenchymal transition in ovarian carcinoma. Front Oncol. 2012;2:33.","journal-title":"Front Oncol"},{"key":"8447_CR6","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/bjc.2016.435","volume":"116","author":"K Lindemann","year":"2017","unstructured":"Lindemann K, Gibbs E, Avall-Lundqvist E, dePont Christensen R, Woie K, Kalling M, et al. Chemotherapy vs tamoxifen in platinum-resistant ovarian cancer: a phase III, randomised, multicentre trial (Ovaresist). Br J Cancer. 2017;116:455\u201363.","journal-title":"Br J Cancer"},{"key":"8447_CR7","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/nrc1123","volume":"3","author":"R Agarwal","year":"2003","unstructured":"Agarwal R, Kaye SB. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer. 2003;3:502\u201316.","journal-title":"Nat Rev Cancer"},{"key":"8447_CR8","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00726-012-1229-7","volume":"44","author":"A Lentini","year":"2013","unstructured":"Lentini A, Abbruzzese A, Provenzano B, Tabolacci C, Beninati S. Transglutaminases: key regulators of cancer metastasis. Amino Acids. 2013;44:25\u201332.","journal-title":"Amino Acids"},{"key":"8447_CR9","doi-asserted-by":"publisher","first-page":"e13390","DOI":"10.1371\/journal.pone.0013390","volume":"5","author":"A Kumar","year":"2010","unstructured":"Kumar A, Xu J, Brady S, Gao H, Yu D, Reuben J, et al. Tissue transglutaminase promotes drug resistance and invasion by inducing mesenchymal transition in mammary epithelial cells. PLoS ONE. 2010;5:e13390.","journal-title":"PLoS ONE"},{"key":"8447_CR10","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1182\/blood.V98.5.1567","volume":"98","author":"SS Akimov","year":"2001","unstructured":"Akimov SS, Belkin AM. Cell surface tissue transglutaminase is involved in adhesion and migration of monocytic cells on fibronectin. Blood. 2001;98:1567\u201376.","journal-title":"Blood"},{"key":"8447_CR11","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s00726-016-2296-y","volume":"49","author":"I Cardoso","year":"2017","unstructured":"Cardoso I, Osterlund EC, Stamnaes J, Iversen R, Andersen JT, Jorgensen TJ, et al. Dissecting the interaction between transglutaminase 2 and fibronectin. Amino Acids. 2017;49:489\u2013500.","journal-title":"Amino Acids"},{"key":"8447_CR12","doi-asserted-by":"publisher","first-page":"e89285","DOI":"10.1371\/journal.pone.0089285","volume":"9","author":"B Yakubov","year":"2014","unstructured":"Yakubov B, Chen L, Belkin AM, Zhang S, Chelladurai B, Zhang ZY, et al. Small molecule inhibitors target the tissue transglutaminase and fibronectin interaction. PLoS ONE. 2014;9:e89285.","journal-title":"PLoS ONE"},{"key":"8447_CR13","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.1038\/sj.onc.1209324","volume":"25","author":"JF Herman","year":"2006","unstructured":"Herman JF, Mangala LS, Mehta K. Implications of increased tissue transglutaminase (TG2) expression in drug-resistant breast cancer (MCF-7) cells. Oncogene. 2006;25:3049\u201358.","journal-title":"Oncogene"},{"key":"8447_CR14","doi-asserted-by":"publisher","first-page":"4704","DOI":"10.1111\/j.1742-4658.2011.08346.x","volume":"278","author":"AM Belkin","year":"2011","unstructured":"Belkin AM. Extracellular TG2: emerging functions and regulation. FEBS J. 2011;278:4704\u201316.","journal-title":"FEBS J"},{"key":"8447_CR15","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1016\/j.febslet.2008.03.053","volume":"582","author":"L Faverman","year":"2008","unstructured":"Faverman L, Mikhaylova L, Malmquist J, Nurminskaya M. Extracellular transglutaminase 2 activates beta-catenin signaling in calcifying vascular smooth muscle cells. FEBS Lett. 2008;582:1552\u20137.","journal-title":"FEBS Lett"},{"key":"8447_CR16","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1096\/fasebj.13.13.1787","volume":"13","author":"ZA Haroon","year":"1999","unstructured":"Haroon ZA, Hettasch JM, Lai TS, Dewhirst MW, Greenberg CS. Tissue transglutaminase is expressed, active, and directly involved in rat dermal wound healing and angiogenesis. FASEB J. 1999;13:1787\u201395.","journal-title":"FASEB J"},{"key":"8447_CR17","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1002\/9781118105771.ch4","volume":"78","author":"SY Kim","year":"2011","unstructured":"Kim SY. Transglutaminase 2: a new paradigm for NF-kappaB involvement in disease. Adv Enzymol Relat Areas Mol Biol. 2011;78:161\u201395.","journal-title":"Adv Enzymol Relat Areas Mol Biol"},{"key":"8447_CR18","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/nrc1588","volume":"5","author":"C Nakanishi","year":"2005","unstructured":"Nakanishi C, Toi M. Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer. 2005;5:297\u2013309.","journal-title":"Nat Rev Cancer"},{"key":"8447_CR19","doi-asserted-by":"publisher","first-page":"34965","DOI":"10.1074\/jbc.M604150200","volume":"281","author":"SS Park","year":"2006","unstructured":"Park SS, Kim JM, Kim DS, Kim IH, Kim SY. Transglutaminase 2 mediates polymer formation of I-kappaBalpha through C-terminal glutamine cluster. J Biol Chem. 2006;281:34965\u201372.","journal-title":"J Biol Chem"},{"key":"8447_CR20","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/j.jmb.2008.10.010","volume":"384","author":"JM Kim","year":"2008","unstructured":"Kim JM, Voll RE, Ko C, Kim DS, Park KS, Kim SY. A new regulatory mechanism of NF-kappaB activation by I-kappaBbeta in cancer cells. J Mol Biol. 2008;384:756\u201365.","journal-title":"J Mol Biol"},{"key":"8447_CR21","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1093\/carcin\/bgn158","volume":"29","author":"L Cao","year":"2008","unstructured":"Cao L, Petrusca DN, Satpathy M, Nakshatri H, Petrache I, Matei D. Tissue transglutaminase protects epithelial ovarian cancer cells from cisplatin-induced apoptosis by promoting cell survival signaling. Carcinogenesis. 2008;29:1893\u20131900.","journal-title":"Carcinogenesis"},{"key":"8447_CR22","doi-asserted-by":"publisher","first-page":"5849","DOI":"10.1158\/0008-5472.CAN-07-6130","volume":"68","author":"JY Hwang","year":"2008","unstructured":"Hwang JY, Mangala LS, Fok JY, Lin YG, Merritt WM, Spannuth WA, et al. Clinical and biological significance of tissue transglutaminase in ovarian carcinoma. Cancer Res. 2008;68:5849\u201358.","journal-title":"Cancer Res"},{"key":"8447_CR23","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/j.1749-6632.1972.tb16322.x","volume":"202","author":"JE Folk","year":"1972","unstructured":"Folk JE. Structure and catalytic properties of hepatic transglutaminase. Ann N Y Acad Sci. 1972;202:59\u201376.","journal-title":"Ann N Y Acad Sci"},{"key":"8447_CR24","doi-asserted-by":"publisher","first-page":"e51136","DOI":"10.1371\/journal.pone.0051136","volume":"7","author":"CJ Groger","year":"2012","unstructured":"Groger CJ, Grubinger M, Waldhor T, Vierlinger K, Mikulits W. Meta-analysis of gene expression signatures defining the epithelial to mesenchymal transition during cancer progression. PLoS ONE. 2012;7:e51136.","journal-title":"PLoS ONE"},{"key":"8447_CR25","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1007\/BF02620867","volume":"24","author":"C van Haaften-Day","year":"1988","unstructured":"van Haaften-Day C, Russell P, Carr S, Wright L. Development and characterization of a human cell line from an ovarian mixed Mullerian tumor (carcinosarcoma). In Vitro Cell Dev Biol. 1988;24:965\u201371.","journal-title":"In Vitro Cell Dev Biol"},{"key":"8447_CR26","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s10585-006-9015-0","volume":"23","author":"CF Singer","year":"2006","unstructured":"Singer CF, Hudelist G, Walter I, Rueckliniger E, Czerwenka K, Kubista E, et al. Tissue array-based expression of transglutaminase-2 in human breast and ovarian cancer. Clin Exp Metastasis. 2006;23:33\u20139.","journal-title":"Clin Exp Metastasis"},{"key":"8447_CR27","doi-asserted-by":"publisher","first-page":"6289","DOI":"10.1038\/sj.onc.1205785","volume":"21","author":"D Matei","year":"2002","unstructured":"Matei D, Graeber TG, Baldwin RL, Karlan BY, Rao J, Chang DD. Gene expression in epithelial ovarian carcinoma. Oncogene. 2002;21:6289\u201398.","journal-title":"Oncogene"},{"key":"8447_CR28","doi-asserted-by":"publisher","first-page":"455","DOI":"10.3390\/cancers10110455","volume":"10","author":"SH Lee","year":"2018","unstructured":"Lee SH, Lee WK, Kim N, Kang JH, Kim KH, Kim SG, et al. Renal cell carcinoma is abrogated by p53 stabilization through Transglutaminase 2 Inhibition. Cancers. 2018;10:455.","journal-title":"Cancers"},{"key":"8447_CR29","doi-asserted-by":"crossref","unstructured":"Kim SY, Keillor JW A. Precision strategy to cure renal cell carcinoma by targeting transglutaminase 2. Int J Mol Sci. 2020;21:2493.","DOI":"10.3390\/ijms21072493"},{"key":"8447_CR30","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41392-021-00701-5","volume":"6","author":"F Yu","year":"2021","unstructured":"Yu F, Yu C, Li F, Zuo Y, Wang Y, Yao L, et al. Wnt\/beta-catenin signaling in cancers and targeted therapies. Signal Transduct Target Ther. 2021;6:307.","journal-title":"Signal Transduct Target Ther"},{"key":"8447_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2024.150348","volume":"729","author":"C Samant","year":"2024","unstructured":"Samant C, Kale R, Pai KSR, Nandakumar K, Bhonde M. Role of Wnt\/beta-catenin pathway in cancer drug resistance: insights into molecular aspects of major solid tumors. Biochem Biophys Res Commun. 2024;729:150348.","journal-title":"Biochem Biophys Res Commun"},{"key":"8447_CR32","doi-asserted-by":"crossref","unstructured":"Katopodis P, Chudasama D, Wander G, Sales L, Kumar J, Pandhal M, et al. Kinase Inhibitors and ovarian cancer. Cancers 2019;11:1357.","DOI":"10.3390\/cancers11091357"},{"key":"8447_CR33","doi-asserted-by":"publisher","first-page":"e35826","DOI":"10.1371\/journal.pone.0035826","volume":"7","author":"P Krejci","year":"2012","unstructured":"Krejci P, Aklian A, Kaucka M, Sevcikova E, Prochazkova J, Masek JK, et al. Receptor tyrosine kinases activate canonical WNT\/beta-catenin signaling via MAP kinase\/LRP6 pathway and direct beta-catenin phosphorylation. PLoS ONE. 2012;7:e35826.","journal-title":"PLoS ONE"},{"key":"8447_CR34","doi-asserted-by":"publisher","first-page":"6257","DOI":"10.3390\/cancers14246257","volume":"14","author":"A Skorda","year":"2022","unstructured":"Skorda A, Bay ML, Hautaniemi S, Lahtinen A, Kallunki T. Kinase Inhibitors in the treatment of ovarian cancer: current state and future promises. Cancers. 2022;14:6257.","journal-title":"Cancers"},{"key":"8447_CR35","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1007\/s00726-018-2635-2","volume":"50","author":"N Kim","year":"2018","unstructured":"Kim N, Kang JH, Lee WK, Kim SG, Lee JS, Lee SH, et al. Allosteric inhibition site of transglutaminase 2 is unveiled in the N terminus. Amino Acids. 2018;50:1583\u201394.","journal-title":"Amino Acids"},{"key":"8447_CR36","doi-asserted-by":"publisher","first-page":"3487","DOI":"10.1096\/fj.12-224220","volume":"27","author":"BM Ku","year":"2013","unstructured":"Ku BM, Kim DS, Kim KH, Yoo BC, Kim SH, Gong YD, et al. Transglutaminase 2 inhibition found to induce p53 mediated apoptosis in renal cell carcinoma. FASEB J. 2013;27:3487\u201395.","journal-title":"FASEB J"},{"key":"8447_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2016.14","volume":"7","author":"JH Kang","year":"2016","unstructured":"Kang JH, Lee JS, Hong D, Lee SH, Kim N, Lee WK, et al. Renal cell carcinoma escapes death by p53 depletion through transglutaminase 2-chaperoned autophagy. Cell Death Dis. 2016;7:e2163.","journal-title":"Cell Death Dis"},{"key":"8447_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2016.99","volume":"7","author":"JH Kang","year":"2016","unstructured":"Kang JH, Lee SH, Kim SY. Discovery of a novel target for renal cell carcinoma: transglutaminase 2. Cell Death Dis. 2016;7:e2200.","journal-title":"Cell Death Dis"},{"key":"8447_CR39","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1073\/pnas.85.4.1057","volume":"85","author":"L Lorand","year":"1988","unstructured":"Lorand L, Dailey JE, Turner PM. Fibronectin as a carrier for the transglutaminase from human erythrocytes. Proc Natl Acad Sci USA. 1988;85:1057\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8447_CR40","doi-asserted-by":"publisher","first-page":"3152","DOI":"10.1073\/pnas.90.8.3152","volume":"90","author":"JT Radek","year":"1993","unstructured":"Radek JT, Jeong JM, Murthy SN, Ingham KC, Lorand L. Affinity of human erythrocyte transglutaminase for a 42-kDa gelatin-binding fragment of human plasma fibronectin. Proc Natl Acad Sci USA. 1993;90:3152\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8447_CR41","doi-asserted-by":"publisher","first-page":"23675","DOI":"10.1074\/jbc.M503323200","volume":"280","author":"J Hang","year":"2005","unstructured":"Hang J, Zemskov EA, Lorand L, Belkin AM. Identification of a novel recognition sequence for fibronectin within the NH2-terminal beta-sandwich domain of tissue transglutaminase. J Biol Chem. 2005;280:23675\u201383.","journal-title":"J Biol Chem"},{"key":"8447_CR42","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.01998","volume":"3","author":"JL Stamos","year":"2014","unstructured":"Stamos JL, Chu ML, Enos MD, Shah N, Weis WI. Structural basis of GSK-3 inhibition by N-terminal phosphorylation and by the Wnt receptor LRP6. Elife. 2014;3:e01998.","journal-title":"Elife"},{"key":"8447_CR43","doi-asserted-by":"crossref","unstructured":"Kim, SY. New insights into development of transglutaminase 2 inhibitors as pharmaceutical lead compounds. Med Sci. 2018;6:87.","DOI":"10.3390\/medsci6040087"},{"key":"8447_CR44","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/nature10166","volume":"474","author":"Cancer Genome Atlas Research N.","year":"2011","unstructured":"Cancer Genome Atlas Research N. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:609\u201315.","journal-title":"Nature"},{"key":"8447_CR45","doi-asserted-by":"publisher","first-page":"18330","DOI":"10.1074\/jbc.M112.339317","volume":"287","author":"L Ai","year":"2012","unstructured":"Ai L, Skehan RR, Saydi J, Lin T, Brown KD. Ataxia-Telangiectasia, Mutated (ATM)\/Nuclear Factor kappa light chain enhancer of activated B cells (NFkappaB) signaling controls basal and DNA damage-induced transglutaminase 2 expression. J Biol Chem. 2012;287:18330\u201341.","journal-title":"J Biol Chem"},{"key":"8447_CR46","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s10549-012-2351-7","volume":"137","author":"KD Brown","year":"2013","unstructured":"Brown KD. Transglutaminase 2 and NF-kappaB: an odd couple that shapes breast cancer phenotype. Breast Cancer Res Treat. 2013;137:329\u201336.","journal-title":"Breast Cancer Res Treat"},{"key":"8447_CR47","first-page":"14914","volume":"272","author":"KC Das","year":"1997","unstructured":"Das KC, White CW. Activation of NF-kappaB by antineoplastic agents. Role of protein kinase C. J Biol Chem. 1997;272:14914\u201320.","journal-title":"Role of protein kinase C. J Biol Chem"},{"key":"8447_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2023.101042","volume":"73","author":"Y Li","year":"2024","unstructured":"Li Y, Zhao B, Peng J, Tang H, Wang S, Peng S, et al. Inhibition of NF-kappaB signaling unveils novel strategies to overcome drug resistance in cancers. Drug Resist Updat. 2024;73:101042.","journal-title":"Drug Resist Updat"},{"key":"8447_CR49","doi-asserted-by":"publisher","first-page":"884","DOI":"10.3390\/brainsci11070884","volume":"11","author":"A Kostic","year":"2021","unstructured":"Kostic A, Jovanovic Stojanov S, Podolski-Renic A, Nesovic M, Dragoj M, Nikolic I, et al. Pyrazolo[3,4-d]pyrimidine tyrosine kinase inhibitors induce oxidative stress in patient-derived glioblastoma cells. Brain Sci. 2021;11:884.","journal-title":"Brain Sci"},{"key":"8447_CR50","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/j.bcp.2006.04.011","volume":"72","author":"G Gloire","year":"2006","unstructured":"Gloire G, Legrand-Poels S, Piette J. NF-kappaB activation by reactive oxygen species: fifteen years later. Biochem Pharmacol. 2006;72:1493\u2013505.","journal-title":"Biochem Pharmacol"},{"key":"8447_CR51","doi-asserted-by":"publisher","first-page":"53725","DOI":"10.1074\/jbc.M407627200","volume":"279","author":"J Lee","year":"2004","unstructured":"Lee J, Kim YS, Choi DH, Bang MS, Han TR, Joh TH, et al. Transglutaminase 2 induces nuclear factor-kappaB activation via a novel pathway in BV-2 microglia. J Biol Chem. 2004;279:53725\u201335.","journal-title":"J Biol Chem"},{"key":"8447_CR52","doi-asserted-by":"publisher","first-page":"4540","DOI":"10.1038\/onc.2015.520","volume":"35","author":"CS Park","year":"2016","unstructured":"Park CS, Kim TK, Kim HG, Kim YJ, Jeoung MH, Lee WR, et al. Therapeutic targeting of tetraspanin8 in epithelial ovarian cancer invasion and metastasis. Oncogene. 2016;35:4540\u20138.","journal-title":"Oncogene"},{"key":"8447_CR53","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s00432-014-1623-5","volume":"140","author":"BM Ku","year":"2014","unstructured":"Ku BM, Kim SJ, Kim N, Hong D, Choi YB, Lee SH, et al. Transglutaminase 2 inhibitor abrogates renal cell carcinoma in xenograft models. J Cancer Res Clin Oncol. 2014;140:757\u201367.","journal-title":"J Cancer Res Clin Oncol"},{"key":"8447_CR54","doi-asserted-by":"publisher","first-page":"e327","DOI":"10.1371\/journal.pbio.0050327","volume":"5","author":"DM Pinkas","year":"2007","unstructured":"Pinkas DM, Strop P, Brunger AT, Khosla C. Transglutaminase 2 undergoes a large conformational change upon activation. PLoS Biol. 2007;5:e327.","journal-title":"PLoS Biol"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08447-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08447-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08447-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T15:04:01Z","timestamp":1770303841000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08447-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,2]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8447"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-08447-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7297143\/v1","asserted-by":"object"}]},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,2]]},"assertion":[{"value":"5 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Soo-Youl Kim established an in-house venture, NCC-Bio Co, under the National Research Grant contract (NRF-2019M3A9G1104345), while adhering to the National Cancer Center\u2019s institutional regulations and holding shares in NCC-Bio Co. Soo-Youl Kim serves as both a principal scientist at the National Cancer Center and the CEO of NCC-Bio, Co., Republic of Korea. However, NCC-Bio Co has no business related to this research.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"199"}}